These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 14092126)

  • 21. Apical and basal uptake of L-dopa and L-5-HTP and their corresponding amines, dopamine and 5-HT, in OK cells.
    Vieira-Coelho MA; Soares-da-Silva P
    Am J Physiol; 1997 May; 272(5 Pt 2):F632-9. PubMed ID: 9176374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Risks in the treatment of parkinsonism with l-dopa and a dopa decarboxylase inhibitor].
    Jörg J
    Med Welt; 1979 Nov; 30(46):1740-2. PubMed ID: 537499
    [No Abstract]   [Full Text] [Related]  

  • 23. Aromatic L-amino acid decarboxylase activity in the rat median eminence, neurointermediate lobe and anterior lobe of the pituitary. Physiological and pharmacological implications for pituitary regulation.
    Johnston CA; Spinedi E; Negro-Vilar A
    Neuroendocrinology; 1984 Jul; 39(1):54-9. PubMed ID: 6205316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
    Burkhard P; Dominici P; Borri-Voltattorni C; Jansonius JN; Malashkevich VN
    Nat Struct Biol; 2001 Nov; 8(11):963-7. PubMed ID: 11685243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [EFFECTS OF RESERPINE, DOPA AND 5-HTP ON THE 2 SLEEP STATES].
    MATSUMOTO J; JOUVET M
    C R Seances Soc Biol Fil; 1964; 158():2137-40. PubMed ID: 14282133
    [No Abstract]   [Full Text] [Related]  

  • 26. [Action of some inhibitors of L-DOPA decarboxylase on the duration of barbiturate narcosis in the mouse].
    HEROLD M; CAHN J; HELBECQUE C; LASJAUNIAS T; JULLIARD AM
    C R Seances Soc Biol Fil; 1962; 156():1270-2. PubMed ID: 13961113
    [No Abstract]   [Full Text] [Related]  

  • 27. Inhibition of DOPA accumulation by rat brain at critical L-DOPA circulating concentrations.
    Horst WD; Bautz G; Renyi E; Spirt N
    Adv Neurol; 1974; 5():369-73. PubMed ID: 4440584
    [No Abstract]   [Full Text] [Related]  

  • 28. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biopterin synthesis defect. Treatment with L-dopa and 5-hydroxytryptophan compared with therapy with a tetrahydropterin.
    McInnes RR; Kaufman S; Warsh JJ; Van Loon GR; Milstien S; Kapatos G; Soldin S; Walsh P; MacGregor D; Hanley WB
    J Clin Invest; 1984 Feb; 73(2):458-69. PubMed ID: 6142058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. INHIBITION OF CEREBRAL DECARBOXYLASE AND BEHAVIOUR.
    PLETSCHER A; PRADAM DA; STEINER FA
    Int J Neuropharmacol; 1964 Dec; 3():550-64. PubMed ID: 14344493
    [No Abstract]   [Full Text] [Related]  

  • 31. POTENT DECARBOXYLASE INHIBITORS. ANALOGS OF METHYLDOPA.
    SLETZINGER M; CHEMERDA JM; BOLLINGER FW
    J Med Chem; 1963 Mar; 6():101-3. PubMed ID: 14188777
    [No Abstract]   [Full Text] [Related]  

  • 32. DECARBOXYLASE ACTIVITY IN VIVO: EFFECTS OF MORPHINE AND ETHANOL PRETREATMENT IN MICE.
    MAYNARD LS; SCHENKER VJ
    Int J Neuropharmacol; 1963 Dec; 2():303-7. PubMed ID: 14119491
    [No Abstract]   [Full Text] [Related]  

  • 33. [STUDIES ON THE STEREOSPECIFICITY OF THE DECARBOXYLASE INHIBITING ACTION OF ALPHA-METHYLDOPA].
    PUETTER J; KRONEBERG G
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1964 Nov; 249():470-8. PubMed ID: 14335181
    [No Abstract]   [Full Text] [Related]  

  • 34. AVOIDANCE BEHAVIOUR IN THE RAT AFTER 5-HYDROXYTRYPTOPHAN (5-HTP) ADMINISTRATION.
    JOYCE D; HURWITZ HM
    Psychopharmacologia; 1964 Jun; 5():424-30. PubMed ID: 14194686
    [No Abstract]   [Full Text] [Related]  

  • 35. A circadian rhythm in 5-hydroxytryptophan decarboxylase? [proceedings].
    Brown F; Nicholass J; Redfern PH
    J Pharm Pharmacol; 1977 Dec; 29 Suppl():56P. PubMed ID: 22688
    [No Abstract]   [Full Text] [Related]  

  • 36. Aromatic L-amino acid decarboxylase enzyme activity in deficient patients and heterozygotes.
    Verbeek MM; Geurtz PB; Willemsen MA; Wevers RA
    Mol Genet Metab; 2007 Apr; 90(4):363-9. PubMed ID: 17240182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. L-dopa hypotension in dogs: evidence for mediation through 5-HT release.
    Antonaccio MJ; Robson RD
    Arch Int Pharmacodyn Ther; 1974 Nov; 212(1):89-102. PubMed ID: 4281293
    [No Abstract]   [Full Text] [Related]  

  • 38. Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study.
    Destée A; Rérat K; Bourdeix I
    Eur Neurol; 2009; 61(2):69-75. PubMed ID: 19039224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interactions of cerebral serotonin and catecholamines].
    Watanabe Y
    Nihon Yakurigaku Zasshi; 1983 May; 81(5):365-83. PubMed ID: 6195056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.